Antibody Avidity in Humoral Immune Responses in Bangladeshi Children and Adults following Administration of an Oral Killed Cholera Vaccine

Abstract

e Antibody avidity for antigens following disease or vaccination increases with affinity maturation and somatic hypermutation. In this study, we followed children and adults in Bangladesh for 1 year following oral cholera vaccination and measured the avidity of antibodies to the T cell-dependent antigen cholera toxin B subunit (CTB) and the T cell-independent antigen lipopolysaccharide (LPS) in comparison with responses in other immunological measurements. Children produced CTB-specific IgG and IgA antibodies of high avidity following vaccination, which persisted for several months; the magnitudes of responses were comparable to those seen in adult vaccinees. The avidity of LPS-specific IgG and IgA antibodies in vaccinees increased significantly shortly after the second dose of vaccine but waned rapidly to baseline levels thereafter. CTB-specific memory B cells were present for only a short time following vaccination, and we did not find significant memory B cell responses to LPS in any age group. For older children, there was a significant correlation between CTB-specific memory T cell responses after the second dose of vaccine and CTB-specific IgG antibody avidity indices over the subsequent year. These findings suggest that vaccination induces a longer-lasting increase in the avidity of antibodies to a T cell-dependent antigen than is measured by a memory B cell response to that antigen and that early memory T cell responses correlate well with the subsequent development of higher-avidity antibodies.

Bivalent oral cholera vaccination induces a memory B cell response to the V. cholerae O1-polysaccharide antigen in Haitian adults

“…We used a standard enzyme-linked immunosorbent assay (ELISA) to measure plasma IgA, IgG and IgM antibody responses to V . cholerae - OSP as described previously[12,13]. OSP was purified and conjugated to bovine serum albumin (BSA) as previously described[14,15].…”

Cholera Toxin B: One Subunit with Many Pharmaceutical Applications

“…In this regard, a more recent work has been performed to evaluate the protective efficacy of Dukoral ® in adults and children [ 25 ]. The study by Alam et al , divided children into 2 groups: young (median age 5) and older (median age 10) and had an adult group with a median age of 32.…”

Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis

“…Cholera patients who were aged 2–5 years had the highest GMF rise from baseline on the seventh day of presentation. Although increases from baseline were comparable in all age groups, vibriocidal antibodies waned earlier and were at baseline levels on the 42nd or 90th day after the first dose [ 26 ].…”